News
Rznomics announces results of preliminary retinal pigmentation in international society
-
- 작성자
- 관리자
-
- 날짜
- 2023-05-09
Proof of efficacy and safety in large animals
Rznomics announced on the 3rd that it has announced the results of a preclinical study of "RZ-004," a candidate for the treatment of Retinitis pigmentationosa, at the American Academy of Ophthalmology (ARVO).
ARVO is the world's largest ophthalmic society founded in 1928. It has more than 10,000 members in more than 75 countries. This year's conference was held in New Orleans, the United States.
The presentation was given by Dr. Archana Jalligampala of the University of Louisville in the United States. The content was the evaluation of the animal model of rhodopsin mutant dominant retinal pigment degeneration targeted by RZ-004. RZ-004 has an RNA editing mechanism that removes mutated rhodopsin ribonucleic acid (RNA) and replaces it with a normal rhodopsin gene. It is in the preclinical completion stage after deriving the final candidate material.
Rznomics said it demonstrated the efficacy of RZ-004 including retinal potentiogram (ERG) through preclinical trials. Toxicity and safety tests are also in the final stages. It is planning to apply for clinical trials with the U.S. Food and Drug Administration (FDA) at the end of the year.
Ji-hyun Kim, a senior researcher at Rznomics, said, "The results of this study are meaningful in that safety and effectiveness have been confirmed in the animal disease model."
Seong-wook Lee, CEO of Rznomics, said, "Tenocular pigment degeneration is in great demand because there are few existing treatments," adding, "Global pharmaceutical companies are also very interested in RZ-004, So I feel a sense of responsibility" He added, "We will do our best to provide innovative treatment opportunities to patients through rapid clinical verification."
Rznomics announced on the 3rd that it has announced the results of a preclinical study of "RZ-004," a candidate for the treatment of Retinitis pigmentationosa, at the American Academy of Ophthalmology (ARVO).
ARVO is the world's largest ophthalmic society founded in 1928. It has more than 10,000 members in more than 75 countries. This year's conference was held in New Orleans, the United States.
The presentation was given by Dr. Archana Jalligampala of the University of Louisville in the United States. The content was the evaluation of the animal model of rhodopsin mutant dominant retinal pigment degeneration targeted by RZ-004. RZ-004 has an RNA editing mechanism that removes mutated rhodopsin ribonucleic acid (RNA) and replaces it with a normal rhodopsin gene. It is in the preclinical completion stage after deriving the final candidate material.
Rznomics said it demonstrated the efficacy of RZ-004 including retinal potentiogram (ERG) through preclinical trials. Toxicity and safety tests are also in the final stages. It is planning to apply for clinical trials with the U.S. Food and Drug Administration (FDA) at the end of the year.
Ji-hyun Kim, a senior researcher at Rznomics, said, "The results of this study are meaningful in that safety and effectiveness have been confirmed in the animal disease model."
Seong-wook Lee, CEO of Rznomics, said, "Tenocular pigment degeneration is in great demand because there are few existing treatments," adding, "Global pharmaceutical companies are also very interested in RZ-004, So I feel a sense of responsibility" He added, "We will do our best to provide innovative treatment opportunities to patients through rapid clinical verification."
- 본사경기도 용인시 수지구 죽전로 152, 단국대학교 소프트웨어ICT관 327호
- TEL. 031-706-8730
- FAX. 031-8018-8734
- E_mailrznomics@rznomics.com
- 기업부설연구소 및 판교지점경기도 성남시 분당구 판교로 253, 판교이노밸리 C동 801호(판교지점), 803호(기업부설연구소)
- TEL. 031-706-8730
Copyright(C) 2019 Rznomics. All Rights Reserved.
